Eli Lilly reported two additional late‑stage diabetes trial wins for orforglipron, an oral GLP‑1 receptor agonist, including superiority versus AstraZeneca’s Farxiga in glycemic control in Type 2 diabetes. The company emphasised the drug’s differentiated profile across diabetes and obesity indications as it prepares regulatory filings. Lilly’s communications focused on reinforcing confidence in the oral GLP‑1 category after market skepticism about commercial uptake and competing modalities. Investors and analysts cited the new data as important validation for orforglipron’s commercial potential in diabetes and as a complementary offering to injectable GLP‑1 agents. The results feed a broader industry push to develop orally bioavailable incretin agents that can expand patient access and reduce barriers associated with injectable therapies.